Details of the Drug
General Information of Drug (ID: DM4EGV0)
| Drug Name |
Linaclotide
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | Linaclotide (USAN) | ||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Affected Organisms |
Humans and other mammals
|
||||||||||||||||||
| ATC Code | |||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight (mw) | 1526.8 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -6.8 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 13 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 19 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 28 | ||||||||||||||||||
| ADMET Property | |||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
| Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||
| Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Irritable bowel syndrome | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | DD91.0 | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
|
Coadministration of a Drug Treating the Disease Different from Linaclotide (Comorbidity)
|
|||||||||||||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
| 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5017). | ||||
|---|---|---|---|---|---|
| 2 | Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. | ||||
| 3 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||


